Redmile Group’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-658,336
| Closed | -$988K | – | 81 |
|
|
2023
Q1 | $988K | Sell |
658,336
-73,043
| -10% | -$110K | 0.04% | 73 |
|
|
2022
Q4 | $731K | Sell |
731,379
-363,266
| -33% | -$363K | 0.03% | 67 |
|
|
2022
Q3 | $1.97M | Hold |
1,094,645
| – | – | 0.08% | 64 |
|
|
2022
Q2 | $3.17M | Hold |
1,094,645
| – | – | 0.12% | 64 |
|
|
2022
Q1 | $3.02M | Sell |
1,094,645
-251,413
| -19% | -$694K | 0.09% | 63 |
|
|
2021
Q4 | $6.27M | Sell |
1,346,058
-2,470,651
| -65% | -$11.5M | 0.14% | 63 |
|
|
2021
Q3 | $32.5M | Buy |
3,816,709
+580,900
| +18% | +$4.94M | 0.57% | 45 |
|
|
2021
Q2 | $53.1M | Sell |
3,235,809
-374,979
| -10% | -$6.15M | 0.79% | 39 |
|
|
2021
Q1 | $79.7M | Buy |
3,610,788
+777,900
| +27% | +$17.2M | 1.12% | 32 |
|
|
2020
Q4 | $87.6M | Buy |
2,832,888
+39,600
| +1% | +$1.22M | 1.06% | 31 |
|
|
2020
Q3 | $56.8M | Buy |
2,793,288
+1,028,100
| +58% | +$20.9M | 1.04% | 33 |
|
|
2020
Q2 | $27.1M | Sell |
1,765,188
-2,100
| -0.1% | -$32.3K | 0.5% | 52 |
|
|
2020
Q1 | $13.7M | Sell |
1,767,288
-31,900
| -2% | -$247K | 0.38% | 50 |
|
|
2019
Q4 | $25.7M | Buy |
1,799,188
+8,900
| +0.5% | +$127K | 0.61% | 43 |
|
|
2019
Q3 | $26.9M | Sell |
1,790,288
-8,928
| -0.5% | -$134K | 0.9% | 34 |
|
|
2019
Q2 | $25.7M | Sell |
1,799,216
-8,040
| -0.4% | -$115K | 0.73% | 42 |
|
|
2019
Q1 | $28.7M | Buy |
+1,807,256
| New | +$28.7M | 0.84% | 40 |
|